We are looking to hire a (Senior) Scientist, B Cell Engineering and CRISPR Genotoxicity. We are looking for highly motivated, experienced, and innovative thinkers to join our growing team of passionate researchers to leverage B cells as a novel class of cellular medicine. This is an exciting opportunity to be part of a foundational team and help build Be Bio!
Must thrive in a fast-paced, growing, and innovative environment where flexibility, resourcefulness, resiliency, and communication skills are key. Excellent interpersonal skills, ability to develop important relationships with your stakeholders, and being an all around good company citizen are essential.
Be Biopharma is pioneering a new class of medicines, unleashing the power of B cells to create the new field of Engineered B Cell Medicines. B cells are the body’s protein producing factories, most widely known for making antibodies. Our leading B cell therapy platform, developed by the top scientific KOLs in the field and with strong IP protection, harnesses this capability to engineer B cells to produce any protein with potential therapeutic application. This creates a unique opportunity to rapidly design and develop a broad portfolio of disease changing products (our platform affords ready swapping in new genes for different disease indications) and to significantly scale the company to realize substantial value in a short period of time.
Importantly, and in contrast to other cell therapy modalities, Engineered B Cells engraft naturally (and thus are not expected to require preconditioning chemotherapy). They are also “naturally allogeneic”, and we expect most or all of our portfolio to be “off-the-shelf” medicines. We have a rich pipeline of initial medicines under development in Oncology and Severe Genetic Disease, and we will subsequently expand to other important indications (e.g. Infectious Disease, Autoimmune Disease, etc).
Our Cambridge-based team is led by highly experienced, mission-driven executives all of whom are experienced cell therapy veterans who played key roles in developing several of today’s most impactful marketed gene and cell therapies. The team is rapidly expanding, with 20 employees joining in the first half of 2021. We are making major strides in our proof-of-concept studies for our lead programs in Oncology and Rare Disease, which are on track for near-term clinical development. Be Biopharma was founded in 2020 with a 52M Series A financing round supported by a syndicate of leading biotech investors (Longwood Fund, Atlas, RA Capital, Alta).